Impact Factor: 2.3

Open Access Published since January 1, 1994

Heterocyclic Communications

ISSN: 2191-0197

Editor-in-chief: Maged Henary

Submit manuscript

About this journal

Topical/Special Issues:

SI Undergraduate Research in the Synthesis of Biologically Active Small Molecules and Their Applications
SI Development of Heterocycles for Biomedical and Bioanalytical Applications

Objective
Heterocyclic Communications (HC) is an open-access, peer-reviewed journal publishing preliminary communications, research articles, and reviews on significant developments in all phases of heterocyclic chemistry, including general synthesis, natural products, computational analysis, considerable biological activity and inorganic ring systems. Clear presentation of experimental and computational data is strongly emphasized. Heterocyclic chemistry is a rapidly growing field. By some estimates original research papers in heterocyclic chemistry have increased to more than 60% of the current organic chemistry literature published. This explosive growth is even greater when considering heterocyclic research published in materials science, physical, biophysical, analytical, bioorganic, pharmaceutical, medicinal and natural products journals. There is a need, therefore, for a journal dedicated explicitly to heterocyclic chemistry and the properties of heterocyclic compounds.

Topics

Development of novel synthetic methods
Significant improvement of known synthetic methods
Chemistry of natural products
Superior biological activity of novel heterocyclic compounds, rational design and synthesis of new drug candidates targeting specific biological receptors
Application of heterocyclic compounds as probes for biomolecules in biophysical and bioanalytical chemistry
Development of new substrates and catalysts in materials chemistry

Article formats
Preliminary Communications, Original Research Articles, Review Articles

Your Benefits

Since 1st January 2019 Heterocyclic Communications has changed the publishing model to Open Access.

Articles accepted for publication in Heterocyclic Communications are subject to an Article Processing Charge of €1500

Your benefits:

Significant developments in heterocyclic chemistry
Synthetic routes to heterocyclic compounds with high biological activity
Imperative topics including theoretical analysis
Cutting-edge trends
Easy traceability through detailed experimental descriptions
Long-time preservation of the content (archiving) with Portico

History

Heterocyclic Communication was previously published by Freund Publishing House Ltd.

Other publications in the field

Abstracting and Indexing

Heterocyclic Communications is covered by the following services:

Baidu Scholar
Cabells Journalytics
Chemical Abstracts Service (CAS) - CAplus
Chemical Abstracts Service (CAS) - SciFinder
Chronos Hub
CNKI Scholar (China National Knowledge Infrastructure)
CNPIEC - cnpLINKer
Dimensions
DOAJ (Directory of Open Access Journals)
EBSCO (relevant databases)
EBSCO Discovery Service
Genamics JournalSeek
GoOA
Google Scholar
Japan Science and Technology Agency (JST)
J-Gate
Journal Citation Reports/Science Edition
JournalGuide
JournalTOCs
KESLI-NDSL (Korean National Discovery for Science Leaders)
MyScienceWork
Naver Academic
Naviga (Softweco)
Primo Central (ExLibris)
ProQuest (relevant databases)
Publons
QOAM (Quality Open Access Market)
ReadCube
Reaxys
Scilit
SCImago (SJR)
SCOPUS
Semantic Scholar
Sherpa/RoMEO
Summon (ProQuest)
TDNet
Ulrich's Periodicals Directory/ulrichsweb
WanFang Data
Web of Science - Current Contents/Physical, Chemical and Earth Sciences
Web of Science - Science Citation Index Expanded
WorldCat (OCLC)
X-MOL
Yewno Discover

Supplementary Materials

Topics

External Links

Volume 29 Issue 1

January 2023

Research Articles

Open Access March 24, 2023

Synthesis, characterization, and antibacterial activity of a new poly azo compound containing N-arylsuccinimid and dibenzobarrelene moieties

Njoya Abdou Salamou, Tamokou Jean-de-Dieu, Sopbué Fondjo Emmanuel, Matsuete Takongmo Germaine, Bitchagno Mbahbou T. Gabin, Peter F. W. Simon, Apollinaire Tsopmo, Kuiate Jules-Roger

Article number: 20220157

More Download PDF

Abstract

The present work describes the synthesis, characterization, and evaluation of the antibacterial activity of a new poly azo compound resulting from the coupling of a previously reported N -arylsuccinimid precursor 5 with the diazonium ion of aniline. This azo compound was characterized using its physical, elemental, and 1D and 2D spectroscopic data. The novel azo compound 7 (minimum inhibitory concentration [MIC] = 16–32 μg/mL) showed higher antibacterial activity than its precursor 5 (MIC = 32–64 μg/mL), although it was low compared to the reference drug ciprofloxacin (MIC = 0.5–4 μg/mL). Graphical abstract

Open Access April 20, 2023

Design, synthesis, and antiviral activities evaluation of novel quinazoline derivatives containing sulfonamide moiety

Yi Deng, Shitao Yin, Xinyun Jing, Yuguo Zheng

Article number: 20220160

More Download PDF

Abstract

A series of novel quinazoline derivatives bearing sulfonamide moiety was designed and synthesized, and their structure were characterized by 1 H NMR, 13 C NMR, and HRMS techniques. Among them, the structure of compound E1 was further confirmed through X-ray single-crystal diffraction analyses. Their anti-Tobacco mosaic virus (TMV) activities were evaluated through half-leaf method. The bioassay results showed that E8 and E19 possess excellent inhibitory activity towards TMV. The EC 50 of curative activities, protective activities, and inactivating activities of E8 and E19 are 132.1, 152.8, 57.4 mg/L and 278.0, 165.3, 94.5 mg/L, respectively, which are far superior than Ribavirin (318.2, 201.5, 128.6 mg/L, respectively).

Open Access June 6, 2023

Design, synthesis, and anticancer activity of novel 4,6-dimorpholinyl-1,3,5-triazine compounds

Jinjing Li, Linbo Li, Yuxiao Liu, Jie Zhang, Chengyang Shi, Shujing Zhou, Hongbin Qiu

Article number: 20220152

More Download PDF

Abstract

A series of novel 4,6-dimorpholinyl-1,3,5-triazine derivatives 6a–6r were obtained through N -substitution and Claisen-Schmidt condensation. 1 H NMR, 13 C NMR, and mass spectrometry were used to characterize the molecular structures of the derivatives. The in vitro antiproliferation activity of derivatives was evaluated using the MTT assay against SW620 (human colon cancer cells), A549 (human nonsmall cell lung cancer cells), HeLa (human cervical cancer cells), and MCF-7 (human breast cancer cells). Compound 6o bearing a pyridyl group exhibited good cytotoxicity against four cancer cells, with IC 50 values of 8.71, 9.55, 15.67, and 21.77 μM, sequentially. In addition, compound 6a showed some selectivity against SW620. Graphical abstract The chalcone structure was introduced into the 4,6-dimorpholinyl-1,3,5-triazine molecule through the C-N bond, and a series of new compounds were obtained. Among them, the pyridyl-containing 6o exhibits anti-proliferation activity similar to that of cisplatin on SW620. Interestingly, the phenyl-containing 6a exhibits a certain selectivity for the anti-proliferation activity of SW620.

Open Access August 31, 2023

Design, synthesis, biological evaluation, and bio-computational modeling of imidazo, thieno, pyrimidopyrimidine, pyrimidodiazepene, and motifs as antimicrobial agents

Maged F. El-Ahwany, Mohamed G. Assy, Mohamed H. Sherif, Mohamed R. Soliman, Abderrahim Titi, Rachid Touzani, Marwa S. El-Gendey, Wesam S. Shehab, Magda H. Abdellattif

Article number: 20220156

More Download PDF

Abstract

In the drug chemistry industry, synthesizing a talented exclusive series of aza-polyheterocyclic compounds was crucial. Aminopyrimidine nucleus reacted with two equivalents of benzaldehyde in the presence of KOH as a starting material to bring about imidazopyrimidine derivative, which experienced intermolecular cyclization using carbon disulfide, Br 2 /AcOH, and/or HNO 2 to produce thiazole, thieno, and/or nitro pyrimidine derivative, respectively. Accordingly, the nucleus of Aminopyrimidine was prepared and used to develop the novel polyheterocyclic systems acylated with two moles of succinic anhydride to furnish the imidazolopyrimidine derivative. Benzylidene ethyl cyanoacetate and aminopyrimidine undergo (3 + 4) intermolecular cycloaddition 1,3 H shift followed by hydrolysis and after CO 2 evolution provided diazepine derivative. The diazepine derivative was attained due to the cyclo-condensation of the starting material and acetylacetone. Moreover, the structure of the novel synthesized compound series was exploited and verified via spectroscopic approaches. The synthesized series were tested for antimicrobial activity against gram-positive and gram-negative bacterial strains and antifungal activity. The thienopyrimidine derivatives and diazepine exhibited unusual antimicrobial activity. Furthermore, the molecular docking studies confirmed the biological studies with Molecular Operating Environment and petro orisis molinspiration studies, which proved the activity of compounds 4, 5, 7, 10, 13 , and 16 .

Open Access September 16, 2023

Synthesis of a novel phosphate-containing ligand rhodium catalyst and exploration of its optimal reaction conditions and mechanism for the polymerization of phenylacetylene

Mingyu Zhang, Yuqi Tang, Rui Xu, Dong Yan, Shuangping Xu, Yanqing Qu, Jingyu Xu, Hongge Jia

Article number: 20220163

More Download PDF

Abstract

Due to the chemical properties of Group VIII transition metals and their importance in catalytic processes, the reactions of rhodium and its neighboring organic complexes have received much attention as model systems. In the present experiments, we successfully prepared two new rhodium complexes named [Rh(cod)(TTP)Cl] and [Rh(cod)(CDP)Cl] using tri( o -tolyl)phosphine and clohexyldiphenylphosphine as ligands, respectively, and the proofs of their structures were completed using 1 H NMR and 13 C NMR. Subsequently, it was applied to the polymerization reaction of phenylacetylene (PA), and the effects of different solvents, time, and temperature on the yield and molecular weight of the polymerization reaction products were discussed. The experimental results show that both complexes can play a catalytic role in the polymerization of PA. From the point of view of polymer molecular weight, the best reaction conditions for both catalysts were 3 h at 20°C in THF solvent (molecular weight up to 2.40 × 10 5 ). From the point of view of yield, the best reaction conditions for both catalysts were 4 h at 35°C in THF solvent (yield up to 89.2%).

SI: Undergraduate Research in the Synthesis of Biologically Active Small Molecules and Their Applications

Open Access February 7, 2023

Preparation of novel acyl pyrazoles and triazoles by means of oxidative functionalization reactions

Geoffrey P. Wadey, Katrina E. Doherty, Arturo León Sandoval, Nicholas E. Leadbeater

Article number: 20220158

More Download PDF

Abstract

Novel acyl pyrazoles and acyl triazoles have been prepared by means of the oxidative amidation of aldehydes in the presence of the requisite azole. Yields range from modest to good in both cases, and some limitations of the substrate scope have been discovered. Acyl pyrazoles were prepared by treatment of a mixture of aldehyde and pyrazole with an oxoammonium salt bearing the nitrate anion. In the case of acyl triazoles, the oxidative functionalization was performed using sodium persulfate as a terminal oxidant in the presence of a catalytic quantity of a nitroxide.

Open Access April 15, 2023

Synthesis and conformational analysis of N-BOC-protected-3,5-bis(arylidene)-4-piperidone EF-24 analogs as anti-cancer agents

Robert B. Smith, William Roberts, Mary Upenieks, Maya Z. Gibson, Michael T. Wentzel, Kyle A. Grice, Sarah K. Zingales

Article number: 20220162

More Download PDF

Abstract

Natural products and their analogs have been explored to stop the progression of cancer cells without unwanted side effects. Chalcones, compounds synthesized naturally in plants, have demonstrated potential as anti-cancer treatments. A library of bis-chalcones that are similar in structure to EF-24, a bis-chalcone molecule known to have anti-cancer properties, has been synthesized in order to examine their medicinal properties. This report highlights the synthesis of ten novel analogs, their anti-cancer activities, and conformational analysis via cryo-NMR and corroboration by density functional theory calculations of the lead compound 1b , tert -butyl 3,5-bis(( E )-4-methylbenzylidene)-4-oxopiperidine-1-carboxylate.

SI: Development of Heterocycles for Biomedical and Bioanalytical Applications

Open Access February 28, 2023

Influence of octreotide on apoptosis and metabolome expression in lipopolysaccharide-induced A549 cells

Luoyang Ruan, Xiaomeng Xu, Jinliang Cao, Xiaohong Xu

Article number: 20220159

More Download PDF

Abstract

Lung cancer shows a high rate of incidence and mortality. This study aimed to investigate the influence of octreotide (OCT) on lipopolysaccharide (LPS)-induced apoptosis and metabolome expression in A549 cells. After A549 cells were treated by LPS or co-cultured with LPS and OCT, cell apoptosis was tested by flow cytometry, and gas chromatography-mass spectrometer (GC/MS) and high-performance liquid chromatography-mass spectrometer (LC/MS) were subjected to determine the differently expressed metabolites, and the interaction network was constructed. Results found that OCT promoted the apoptosis of A549 cells and significantly affected LPS-regulated cell apoptosis. Following the further investigation by orthogonal partial least squares discriminant analysis (OPLS-DA), the metabolites with different expression levels were obtained, and most of which belong to amino acids, phospholipids, organic acid, and saccharides. Fourteen components with the role of the marker metabolites included serotonin, indole, threonine, serine, glucose, phenylalanine, lactose, fumarate, 4-hydroxyphenyllactate, aspartate, asparagine, putrescine, proline, and succinate. It is indicated that OCT promotes apoptosis through five metabolism pathways and 14 key metabolism elements in A549 cells.

Open Access April 20, 2023

Crude extract of J1 fermentation promotes apoptosis of cervical cancer cells

Xia Yu, Qing He, Wei Zhao, Shuo Zhang, Haixia Du, Zhengyu Lin, Xiaohui Han, Jingjun Peng

Article number: 20220161

More Download PDF

Abstract

Cervical cancer is a typical cancer characterized by abnormal cell growth in the cervical area. Ginkgo biloba L. is a deciduous tree of the genus Ginkgo , possessing anti-cancer effects. The aim of this study was to explore the effect of strain J1 from Ginkgo biloba L. on apoptosis of cervical cancer cells. Bacteriostatic activity test, MTT assay and Flow cytometry were used in this study. Crude extract of J1 fermentation reduced cell growth in cervical cancer. The crude extract of the fermentation broth of strain J1 had a good inhibitory effect on Staphylococcus aureus . The crude extract of the J1 fermentation had no toxic effect on normal WISH cells in the range of anti-cervical cancer concentration. Crude extract of J1 fermentation induced apoptosis and regulated cell cycle in cervical cancer. The active compounds were separated and identified by preparative chromatography, and more than ten compounds were obtained. Our study suggests that the crude extract of J1 fermentation from Endophytic fungi of Ginkgo biloba reduced cell growth, and promoted apoptosis of cervical cancer, and is a potential therapeutic strategy for the treatment of cervical carcinoma.

Volume 24 (2018)

Volume 23 (2017)

Volume 22 (2016)

Volume 21 (2015)

Volume 20 (2014)

Volume 19 (2013)

Volume 18 (2012)

Volume 17 (2011)

Volume 16 (2010)

Volume 15 (2009)

Volume 14 (2008)

Volume 13 (2007)

Volume 12 (2006)

Volume 11 (2005)

Volume 10 (2004)

Volume 9 (2003)

Volume 8 (2002)

Volume 7 (2001)

Volume 6 (2000)

Volume 5 (1999)

Volume 4 (1998)

Volume 3 (1997)

Volume 2 (1996)

Volume 1 (1995)

Journal Impact Factor	2.3	2022, Journal Citation Reports (Clarivate, 2023)
5-year Journal Impact Factor	1.8	2022, Journal Citation Reports (Clarivate, 2023)
Journal Citation Indicator	0.49	2022, Journal Citation Reports (Clarivate, 2023)
CiteScore	3.4	2022, Scopus (Elsevier B.V., 2023)
SCImago Journal Rank	0.305	2022, SJR (Scimago Lab, 2023; Data Source: Scopus)
Source Normalized Impact per Paper	0.722	2022, CWTS Journal Indicators (CWTS B.V., 2023; Data Source: Scopus)

More information about journal rankings

Submit

Manuscripts should be submitted to the journal via online submission system Editorial Manager available for this journal at https://www.editorialmanager.com/hcc In case of problems, please contact the Editorial Office of this journal at Izabela.Zarczynska@degruyter.com.

EDITORIAL POLICY

Unpublished material: Submission of a manuscript implies that the work described is not copyrighted, published or submitted elsewhere, except in abstract form. The corresponding author should ensure that all authors approve the manuscript before its submission.
Ethical conduct of research: The authors must describe and confirm safeguards to meet ethical standards when applicable. See Editorial Policy for details.
Conflict of interest: When authors submit a manuscript, they are responsible for recognizing and disclosing financial and/or other conflicts of interest that might bias their work and/or could inappropriately influence his/her judgment. If no specified acknowledgement is given, the Editors assume that no conflict of interest exists. Authors are encouraged to fill in the ICMJE Conflicts of Interest Form (available here) and send it in the electronic format to the Managing Editor.
Copyright: All authors retain copyright, unless – due to their local circumstances – their work is not copyrighted. The copyrights are governed by the Creative-Commons Attribution Only license (CC-BY) which is compliant with Plan-S. We may also publish a paper under CC-BY-NC-ND license on author's request. The corresponding author grants the journal the license to use of the article, by signing the License To Publish. Scanned copy of license should be sent to the journal, as soon as possible.
Authorship: Authorship should be limited to those who have made a significant contribution to the conception, design, execution, or interpretation of the reported study. All those who have made significant contributions should be listed as co-authors. Where there are others who have participated in certain substantive aspects of the research project, they should be named in an Acknowledgement section. The corresponding author should ensure that all appropriate co-authors (according to the above definition) and no inappropriate co-authors are included in the author list of the manuscript, and that all co-authors have seen and approved the final version of the paper and have agreed to its submission for publication.
Peer Review process: Our standard policy requires each paper to be reviewed by at least two Referees and the peer-review process is single-blind. The Editors reserve the right to decline the submitted manuscript without review, if the studies reported are not sufficiently novel or important to merit publication in the journal. Manuscripts deemed unsuitable (insufficient originality or of limited interest to the target audience) are returned to the author(s) without review. The Editor seeks advice from experts in the appropriate field. Research articles and communications are refereed by a minimum of two reviewers, review papers by at least three. Authors are requested to suggest persons competent to review their manuscript. However, please note that this will be treated only as a suggestion, and the final selection of reviewers is exclusively the Editor's decision. The final decision of acceptance in made by Managing Editor or, in case of conflict, by the Editor-in-Chief.
Scientific Misconduct: This journal publishes only original manuscripts that are not also published or going to be published elsewhere. Multiple submissions/publications, or redundant publications (re-packaging in different words of data already published by the same authors) will be rejected. If they are detected only after publication, the journal reserves the right to publish a Retraction Note. In each particular case Editors will follow COPE’s Core Practices and implement the advices.

Editorial

Editor-in Chief
Maged Henary, Department of Chemistry, Georgia State University, Atlanta, USA

Managing Editor
Izabela Żarczynska
Izabela.Zarczynska@degruyter.com

Honorary Editor
Lucjan Strekowski, Georgia State University, Atlanta, USA

Associate Editors
Alfons Baumstark, Georgia State University, Atlanta, USA
Naresh Gunaganti, Northeastern University, Boston, USA
Yuliang Li, Chang’an University, China
Ajay Mallia, Georgia Gwinnett College, Lawrenceville, USA
Sarbjit Singh, University of Nebraska Medical Center, Omaha, USA
Subhash D. Tanpure, Adesis Inc. - A Universal Display Company, Delaware, USA
Kun Zhao, Chubu University, Kasugai, Japan
Wei Zhu, Northwestern University, Evanston, USA

Assistant Editor
Headar Abuirqeba, Catholic University of America, Washington DC, USA

Editorial Board
S. Abu-Orabi, Association of Arab Universities, Amman, Jordan
S. Achilefu, Washington University, St. Louis, USA
E.B. Arevalo-Garcia, Educational Research Institute, Warsaw, Poland
M. Brimble, University of Auckland, Auckland, New Zealand
R.A. Bunce, Oklahoma State University, Stillwater, USA
D. Das, Johns Hopkins School of Medicine, Baltimore, USA
M. Elliott, University of Cardiff, Cardiff, UK
D.C. Gautam, University of Rajasthan, Jaipur, India
M.W. Germann, Georgia State University, Atlanta, USA
S. Gozem, Georgia State University, Atlanta, USA
D. Hamelberg, Georgia State University, Atlanta, USA
H. Kiyota, Okayama University, Okayama, Japan
K. Kiec-Kononowicz, Jagiellonian University, Kraków, Poland
M. Kumar, University of Rajasthan, Jaipur, India
H. Nishino, Kumamoto University, Kumamoto, Japan
T. Okano, Jikei University, Tokyo, Japan
S.S. Panda, Augusta University, Augusta, USA
S.E. Patterson, UMN Center for Drug Design, Minneapolis, USA
J. Reddy, Dr. Jagath Reddy's Heterocyclics, Hyderabad, India
S. Routier, University of Orléans, Orléans, France
A. Rykowski, University of Podlasie, Siedlce, Poland
S.W. Schneller, University of Auburn, Auburn, USA
B.C.G. Söderberg, University of West Virginia, Morgantown, USA
V. Traven, Russian University of Chemical Technology, Moscow, Russia
B. Wang, Georgia State University, Atlanta, USA
K. Weisz, Ernst Moritz Arndt University, Greifswald, Germany
P.-F. Xu, Lanzhou University, Lanzhou, China
P. Zajdel, Jagiellonian University Medical College, Kraków, Poland
N. Zaware, Mount Sinai School of Medicine, New York, USA
A. Zawisza, University of Łódź, Łódź, Poland

Language Editors
Stephen Hill, The ōbex project, UK
Alison Jones, The ōbex project, UK
Joanna Cave, The ōbex project, UK
Rosie Madge, The ōbex project, UK
Martin Owton, The ōbex project, UK
Hugh Patrick, The ōbex project, UK
Nour Tanbouza, The ōbex project, UK
Amy Catherine Angie Verhagen, The ōbex project, UK
Rebecca Williams, The ōbex project, UK
Rachel Whiteside, The ōbex project, UK

Publisher
DE GRUYTER Poland
Bogumiła Zuga 32A Str.
01-811 Warsaw, Poland
T: +48 22 701 50 15

Editorial Contact
Izabela Żarczynska
Izabela.Zarczynska@degruyter.com

(Deutsch)

Type: Journal
Language: English
Publisher: De Gruyter
First published: January 1, 1994
Publication Frequency: 1 Issue per Year
Audience: researchers in the field of heterocyclic, bioorganic, bioinorganic and medicinal chemistry